Dose Escalation Study of PF-06741086 In Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Healthy

Interventions

BIOLOGICAL

PF-06741086

PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

DRUG

Placebo

Placebo for PF-06741086, single dose

Trial Locations (1)

Pfizer Clinical Research Unit, Brussels